Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 October 2024 | Story André Damons | Photo Supplied
Prof-Maryke-Labuschagne
Prof Maryke Labuschagne is a Professor of Plant Breeding in the UFS Department of Plant Sciences.

A new research chair at the University of the Free State (UFS), led by Prof Maryke Labuschagne, a Professor of Plant Breeding in the UFS Department of Plant Sciences, hopes to increase food and nutritional security in South Africa through crops that have intrinsic high nutritional value.

The Breeding Climate-Resilient Vegetables and Grains research chair was established in partnership with the Agricultural Research Council (ARC) and the Department of Agriculture, Land Reform and Rural Development (DALRRD). It will be hosted within the Faculty of Natural and Agricultural Sciences (NAS) alongside the other ARC-DALLRD-UFS research chairs, namely Climate Change and Agriculture, Innovative Agro-processing for Climate-smart Food System, Agriculture Risk Financing and Sustainable Livestock Production. 

The aim of the new ARC-DALLRD-UFS research chair, explains Prof Labuschagne, who is also leading the National Research Foundation (NRF) SARChI Chair in Diseases and Quality of Field Crops, is to breed climate resilient crops with high levels of nutrients such as iron, zinc, provitamin A and essential amino acids, as well as disease resistance, in collaboration with the ARC.

Breeding of climate resilient crops

“We are all aware of the need for food security in South Africa. Climate change is already negatively impacting food production. With this research chair, in collaboration with the ARC, we hope to increase food security through crops that have intrinsic high nutritional value, for example, high levels of iron and zinc and provitamin A, of which there are high levels of deficiency in our population, and at the same time increase climate resilience (such as heat and drought tolerance) in these crops.

“We will be working on breeding climate-resilient, nutrient-rich and disease-resistant pigeon pea and cowpea cultivars; maize rich in provitamin A, iron and zinc; highly nutritious sweet and bitter sorghum; rust-resistant and good-quality wheat; high-yielding and nutritious indigenous vegetables such as amaranth and amadumbi; and research on potato, sweet potato and cassava for human and industrial uses,” says Prof Labuschagne.

The new chair will complement the research that is already being done for the SARChI chair, but with the ARC as partner. It will combine the expertise and resources of Plant Breeding at the UFS with that of the ARC-VIMP (Vegetable, Industrial and Medicinal Plants), ARC-GC (Grain Crops) and ARC-SC (Small Grains). The chair research will include orphan crops such as cowpea, pigeon pea and indigenous vegetables, as well as root and tuber crops such as potato and cassava, and cereals such as wheat, maize and sorghum.

Collaborative research

“The focus of this chair is on collaborative research and student training with the ARC, but the research area will still focus on the development of nutrient-rich and disease-resistant food-security crops. It will also have an additional focus of climate resilience, and the inclusion of orphan crops indigenous to Africa and South Africa.”

Prof Labuschagne says it is exciting that collaborative research can now be done with the unique expertise and resources (laboratory equipment, fields, greenhouses etc.) of several research institutes for the benefit of food and nutritional security in South Africa. Doing this research in a large team with lots of expertise in different areas will certainly yield more and better results with a larger impact on food security.

“This is a very exciting development in agricultural research now that we are part of a large team all working towards the same goal of improving food security, sharing expertise and resources and also doing collaborative training of MSc and PhD students who will become the scientists of tomorrow, taking this quest into the future.”

Prof Vasu Reddy, Deputy Vice-Chancellor: Research and Internationalisation, says this chair is aligned to the UFS Vision 130 strategy, shaped by excellence and impact, sustainability and society. “This distinguished chair led by Prof Labuschagne recognises exceptional achievement and pre-eminence in the field to catalyse and ignite new talent and new knowledge. It marks an exciting opportunity to deepen our understanding of breeding climate-resilient vegetables and grains aligned to our expertise in agriculture.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept